Pivot, X., & Marmé, F. (2018). Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast cancer, 25(3), . https://doi.org/10.1007/s12282-017-0826-4
Chicago-Zitierstil (17. Ausg.)Pivot, Xavier, und Frederik Marmé. "Subgroup Analysis of Patients with HER2-negative Metastatic Breast Cancer in the Second-line Setting from a Phase 3, Open-label, Randomized Study of Eribulin Mesilate Versus Capecitabine." Breast Cancer 25, no. 3 (2018). https://doi.org/10.1007/s12282-017-0826-4.
MLA-Zitierstil (9. Ausg.)Pivot, Xavier, und Frederik Marmé. "Subgroup Analysis of Patients with HER2-negative Metastatic Breast Cancer in the Second-line Setting from a Phase 3, Open-label, Randomized Study of Eribulin Mesilate Versus Capecitabine." Breast Cancer, vol. 25, no. 3, 2018, https://doi.org/10.1007/s12282-017-0826-4.